NURECA  Financial Statement Analysis 
                    
                    
                                                         
                                
                                                
                     | 
                        
                        
                        
                        
                    ||
| 
                            The Revenues of NURECA  have increased by 19.29% YoY .
                             The Earnings Per Share (EPS) of NURECA has increased by Positive YoY.  | 
                    ||
| REVENUES | 
| OPERATING MARGIN | 
| PROFIT AFTER TAX | 
| EPS | 
| ROCE | 
NURECA  Last 5 Annual Financial Results
 [BOM: 543264|NSE : NURECA] 
            | Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | 
|---|---|---|---|---|---|
| Revenues | ₹110 Cr | ₹92 Cr | ₹111 Cr | ₹256 Cr | ₹213 Cr | 
| Expenses | ₹117 Cr | ₹102 Cr | ₹126 Cr | ₹200 Cr | ₹152 Cr | 
| Operating Profit (Excl OI) | ₹-7.81 Cr | ₹-10 Cr | ₹-15 Cr | ₹56 Cr | ₹62 Cr | 
| Other Income | ₹13 Cr | ₹11 Cr | ₹7.11 Cr | ₹7.70 Cr | ₹2.82 Cr | 
| Interest | ₹1.21 Cr | ₹0.49 Cr | ₹0.45 Cr | ₹0.74 Cr | ₹1.60 Cr | 
| Depreciation | ₹2.34 Cr | ₹2.36 Cr | ₹2.39 Cr | ₹1.48 Cr | ₹0.42 Cr | 
| Profit Before Tax | ₹1.34 Cr | ₹-2.54 Cr | ₹-11 Cr | ₹61 Cr | ₹62 Cr | 
| Profit After Tax | ₹0.85 Cr | ₹-1.79 Cr | ₹-8.25 Cr | ₹45 Cr | ₹46 Cr | 
| Consolidated Net Profit | ₹0.85 Cr | ₹-1.79 Cr | ₹-8.25 Cr | ₹45 Cr | ₹46 Cr | 
| Earnings Per Share (Rs) | ₹0.85 | ₹-1.79 | ₹-8.25 | ₹44.96 | ₹46.37 | 
| PAT Margin (%) | 0.69 | -1.79 | -7.08 | 16.64 | 20.62 | 
| ROE(%) | 0.44 | -0.92 | -4.14 | 24.55 | 52.39 | 
| ROCE(%) | 1.31 | -1.06 | -5.17 | 33.57 | 67.61 | 
| Total Debt/Equity(x) | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 
Key Financials | 
                        ||
| Market Cap | : | ₹ 257.0 Cr | 
| Revenue (TTM) | : | ₹ 130.1 Cr | 
| Net Profit(TTM) | : | ₹ 4.1 Cr | 
| EPS (TTM) | : | ₹ 4.1 | 
| P/E (TTM) | : | 62.6 | 
| Industry Peers & Returns | 1W | 1M | 1Y | 
| NURECA | -10.8% | 11.7% | -7.8% | 
| POLY MEDICURE | 0.5% | -1.9% | -22.2% | 
NURECA  Revenues
 [BOM: 543264|NSE : NURECA]  
                        | Y-o-Y | 19.29 %  | 
                                
| 5 Yr CAGR | -15.34 %  | 
                                
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹110 Cr | 19.29 | |
| Mar2024 | ₹92 Cr | -17.42 | |
| Mar2023 | ₹111 Cr | -56.44 | |
| Mar2022 | ₹256 Cr | 19.72 | |
| Mar2021 | ₹213 Cr | - | |
NURECA  Operating Profit
 [BOM: 543264|NSE : NURECA]  
                    | Y-o-Y | Negative  | 
                        
                        
| 5 Yr CAGR | Negative  | 
                        
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹-7.81 Cr | Negative | |
| Mar2024 | ₹-10 Cr | Negative | |
| Mar2023 | ₹-15 Cr | Negative | |
| Mar2022 | ₹56 Cr | -9.80 | |
| Mar2021 | ₹62 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | Negative  | 
                        
| 5 Yr CAGR | Negative  | 
                        
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | -7.12% | Negative | |
| Mar2024 | -11.13% | Negative | |
| Mar2023 | -13.48% | Negative | |
| Mar2022 | 21.72% | -24.66 | |
| Mar2021 | 28.83% | - | |
NURECA  Profit After Tax
 [BOM: 543264|NSE : NURECA]  
            | Y-o-Y | Positive  | 
                    
                    
| 5 Yr CAGR | -63.25 %  | 
                    
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹0.85 Cr | Positive | |
| Mar2024 | ₹-1.79 Cr | Negative | |
| Mar2023 | ₹-8.25 Cr | Negative | |
| Mar2022 | ₹45 Cr | -3.05 | |
| Mar2021 | ₹46 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Positive  | 
                    
| 5 Yr CAGR | -57.23 %  | 
                    
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 0.69 % | Positive | |
| Mar2024 | -1.79 % | Negative | |
| Mar2023 | -7.08 % | Negative | |
| Mar2022 | 16.64 % | -19.30 | |
| Mar2021 | 20.62 % | - | |
NURECA  Earnings Per Share (EPS)
 [BOM: 543264|NSE : NURECA]  
            | Y-o-Y | Positive  | 
                    
                    
| 5 Yr CAGR | -63.20 %  | 
                    
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹0.85 | Positive | |
| Mar2024 | ₹-1.79 | Negative | |
| Mar2023 | ₹-8.25 | Negative | |
| Mar2022 | ₹45 | -3.04 | |
| Mar2021 | ₹46 | - | |
NURECA  Return on Capital Employed (ROCE)
 [BOM: 543264|NSE : NURECA]  
            | Y-o-Y | Positive  | 
                    
                    
| 5 Yr CAGR | -62.69 %  | 
                    
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 1.31% | Positive | |
| Mar2024 | -1.06% | Negative | |
| Mar2023 | -5.17% | Negative | |
| Mar2022 | 33.57% | -50.35 | |
| Mar2021 | 67.61% | - | |
NURECA Share Price vs Sensex
| Current Share Price | : | ₹257.0 | 
| Current MarketCap | : | ₹ 257.0 Cr | 
| Updated EOD on | : | Nov 03,2025 | 
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year | 
| NURECA |    -10.8%  | 
                            
                     
                     11.7%  | 
                     
                     -7.8%  | 
                    
| SENSEX |    -0.9%  |    
                      
                    
                     4.6%  | 
                     
                     5%  | 
                    
NURECA related INDICES
You may also like the below Video Courses
FAQ about NURECA Financials
How the annual revenues of NURECA have changed ?
The Revenues of NURECA have increased by 19.29% YoY .
How the Earnings per Share (EPS) of NURECA have changed?
The Earnings Per Share (EPS) of NURECA has increased by Positive YoY .
|                         
                        Intrinsic Value of POLY MEDICURE LTD Intrinsic Value of NURECA LTD  |